TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00926003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Computerized cognitive training
Description: 8 weeks of 3 times weekly intervention for 60 min per session with the full titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Limited computerized cognitive training
Description: Locked Captain's Log CCRT that rotates randomly among simplest level of computer cognitive games training. 8 weeks of 3 times weekly intervention for 60 min per session with the non-titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning).
Study: NCT01589562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megace 800mg/20ml
Description: Megestrol acetate 800mg/20ml, Suspension, Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-ES(B) 625mg/5ml
Description: Megestrol acetate 625mg/5ml, Nano suspension, Single dose
Study: NCT02109198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active CN-NINM PoNS
Description: Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham CN-NINM PoNS
Description: Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
Study: NCT02698683

Intervention type: OTHER
Intervention: lymphocyte count
Description: lymphocyte count

Intervention type: OTHER
Intervention: lymphocyte count
Description: lymphocyte count
Study: NCT01338922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion therapy
Description: Insulin is given continuously using an insulin pump. Devices are allowed having marketing approval. Insulins are permitted with marketing approval.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily injection therapy
Description: Multiple daily injection therapy with different devices and insulin types. Devices and insulin types have to have marketing approval.
Study: NCT03301090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03482297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo will be given three times a day on the baseline day (placebo)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Oral placebo will be given three times a day on the baseline day (placebo)
Study: NCT03301090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03482297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: A midodrine pill 10mg will be given three times a day on the standard of care study day
Study: NCT03301090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3048
Description: REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3048
Description: REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3048
Description: REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3048
Description: REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3048
Description: REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3048
Description: REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.
Study: NCT03482297

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Midodrine
Description: A midodrine pill 10mg will be given three times a day on the standard of care study day
Study: NCT03977753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2LVERU® or 2LVERU® JUNIOR
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study: NCT04020692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EOPC Intervention
Description: The issue of drug continuity after hospital discharge has become a major issue in recent years. When patients return home, the drugs taken do not correspond to the treatments prescribed at the end of the hospitalization. This is due to appropriate or inappropriate initiatives of the patients (or their relatives) and/or the physicians accompanying them. Prescribed medications, on the other hand, are almost always dispensed by community pharmacists.~The scope chosen in this project is that the intervention of an operational clinical pharmacy team (EOPC), targeting both patient and health care professionals (inpatient and outpatient), will maintain, in outpatient care, the drugs treatments that have been optimized during hospitalization.
Study: NCT02611570

Intervention type: OTHER
Intervention: LDCT
Description: LDCT at enrollment, annually for two years and biennially for 6 years if no lung cancer is detected
Study: NCT04481230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg
Description: 1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg (D0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg
Description: 1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg (D0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
Description: 1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (D0)
Study: NCT03301090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3051
Description: REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3051
Description: REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3051
Description: REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3051
Description: REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3051
Description: REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3051
Description: REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
Study: NCT01022801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks
Study: NCT02401308

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation surgery
Description: Deep Brain Stimulation surgery: awake vs. asleep

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation surgery
Description: Deep Brain Stimulation surgery: awake vs. asleep
Study: NCT00984360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 380mg extended-release, given once by intramuscular gluteal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 380mg extended-release, given once by intramuscular gluteal injection
Study: NCT02139423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CMV PCR
Study: NCT01736501

Intervention type: OTHER
Group type: OTHER
Intervention: Genetics education at baseline

Intervention type: OTHER
Group type: OTHER
Intervention: Genetics education at baseline

Intervention type: OTHER
Group type: OTHER
Intervention: Hypothetical genomic scenarios at follow-up

Intervention type: OTHER
Group type: OTHER
Intervention: Hypothetical genomic scenarios at follow-up
Study: NCT01450605

Intervention type: DRUG
Intervention: No Intervention
Description: Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time
Study: NCT01103960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan80mg+Amlodipine5mg
Description: combination therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 5mg
Description: monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan80mg+Amlodipine 5mg
Description: combination therapy
Study: NCT04100512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillating Positive Expiratory Pressure Device
Description: Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device is a drug-free, easy to use, hand-held device with a proprietary pressure-oscillation dynamic that provides intermittent resistance and creates positive pressure and oscillations simultaneously. The Aerobika® OPEP device opens weak or collapsed airways to mobilize and assist mucociliary clearance to the upper airways where it can be coughed out.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive spirometry
Description: An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
Study: NCT02578914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS2 Ophthalmic Drops (0.5%)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: NS2 Ophthalmic Drops Vehicle (0.0%)
Study: NCT01215214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam: 3mg iv
Study: NCT01032044

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard endoscopic evaluation
Description: Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pCLE guided evaluation
Description: Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.
Study: NCT02875834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS) 10g
Description: Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS) 5g
Description: Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS) 10g
Description: Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
Study: NCT03638999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Trometamol 30Mg/1mL Injection
Description: Subjects in the intervention group will receive intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Subjects in the control group will receive 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure.
Study: NCT03344692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: prefilled pen containing 75 mg of Praluent (Alirocumab) in 1 ml of solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: prefilled pen containing 1 ml of solution without Praluent
Study: NCT01118260

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total intravenous anaesthesia
Description: propofol and remifentanil

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anaesthesia
Description: bupivacaine and fentanyl
Study: NCT03976687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral tablets
Study: NCT01524939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunoglobulin G
Description: Intravenously administer a single dose of the product (2g/kg) for at least 12 hours
Study: NCT02105246

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral to home-based cardiac rehab
Description: Home-based cardiac rehab is a 12 week, home-based lifestyle intervention that includes counseling regarding heart healthy lifestyle changes.
Study: NCT02875834

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
Study: NCT02876172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Two sessions of MDMA-assisted therapy, one with an initial dose of 75 mg (and optional supplemental dose of 37.5 mg) and the second with 75 or 100 mg MDMA (with optional supplemental dose of either 37.5 mg or 50 mg respectively) given to the participant with PTSD and their significant other.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT
Description: A three-phase, 15-session, manualized treatment from the CBCT manual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Non-directive therapy (from the Multidisciplinary Association for Psychedelic Studies MDMA-assisted therapy treatment manual)
Study: NCT03342053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7234292 (RG6042)
Description: Intrathecal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7234292 (RG6042)
Description: Intrathecal injection
Study: NCT03696719

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS bispectral index monitoring device
Description: In addition to the standard monitoring prescribed by the American society of Anesthesiologists, all study participants will be monitored with the BIS, a noninvasive monitoring device which measures the depth of anesthesia. The monitoring is performed using noninvasive electrodes placed on the forehead.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NSE cerebral biomarker testing
Description: Venous blood will be collected from each participant in the surgery room prior to anesthesia induction, throughout anesthesia and one hour following surgery in the PACU in order to assess NSE cerebral biomarker according to the ELISA method requirements. At each one of the assessment points 9 cc of venous of blood will be taken from each of the study participants, while routine blood tests are taken.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NSE cerebral biomarker testing
Description: Venous blood will be collected from each participant in the surgery room prior to anesthesia induction, throughout anesthesia and one hour following surgery in the PACU in order to assess NSE cerebral biomarker according to the ELISA method requirements. At each one of the assessment points 9 cc of venous of blood will be taken from each of the study participants, while routine blood tests are taken.
Study: NCT02105246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to center-based cardiac rehab
Description: Center-based cardiac rehab is a health center-based cardiac rehabilitation program that involves counseling in healthy heart behaviors and exercise delivered in a clinical setting.
Study: NCT03881930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance rehabilitation with modified visual input
Description: Patients will perform the exercises alternatively: while keeping their eyes closed or their vision will be obstructed by a opaque mask or disturbed by moving luminous dots projected on the environment in a dark room without any visual reference cues.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance rehabilitation with no modified visual input
Description: Patients will perform the exercises while keeping their eyes openned
Study: NCT01456234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir 75 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 75 mg BID
Study: NCT03265990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ligasure haemroidectomy
Description: In ligasure group,After the haemorrhoids are prolapsed out from the anal canal with an artery forceps,Ligasure haemorrhoidectomy will be performed by applying the ligasure forceps close to the edge of each pile.Repeated applications of the device will be performed and excision will be continued into the anal canal,lifting the pile from the internal anal sphincter,to the level of the vascular pedicle,which will be finally divided.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional haemorrhoidectomy
Description: According to the Ferguson technique~* Manual anal sphincter stretching up to 4 fingers~* Delivery of hemorrhoidal masses with artery forceps,one being applied at the base of haemorrhoid,the other at the apex.~* skin incision at the base of haemorrhoids and submucosal dissection to lift the haemorrhoid mass off the internal sphincter.~After this the haemorrhoid pedicle will be transfixed and the mucosal edges of the defect will be opposed.
Study: NCT01586312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogenic mesenchymal stromal cells injection
Description: Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)
Study: NCT03620643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib Oral Capsule [Xalkori]
Description: Crizotinib 250 mg Crizotinib 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib Oral Capsule [Xalkori]
Description: Crizotinib 250 mg Crizotinib 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]
Description: Fulvestrant (Faslodex or generic) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.
Study: NCT01362556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Administration of a calculated amount of sodium bicarbonate 8% \[SB\] after arterial blood gas measurement according to Base Excess \[BE\] and Body weight \[kg\].~Formula: SB \[ml\] = -BE \* kg \* 0.1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Administration of a calculated amount of sodium chloride 0.9% \[SC\] after arterial blood gas measurement according to Base Excess \[BE\] and Body weight \[kg\].~Formula: SC \[ml\] = -BE \* kg \* 0.1
Study: NCT01327118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin F2alpha
Description: intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isoton sodium chloride
Description: intravenous injection